Molecular Syndromology
Foundation S, Orphan ON, Suisse F, La P, Sur R, Maladies LES, Svizzera F, La PER, Sulle R, Orfane M
Molecular Syndromology - vol. 6 304-335 (2016)
Foundation S, Orphan ON, Suisse F, La P, Sur R, Maladies LES, Svizzera F, La PER, Sulle R, Orfane M
Molecular Syndromology - vol. 6 304-335 (2016)
Cappato S, Tonachini L, Giacopelli F, Tirone M, Galietta LJV, Sormani M, Giovenzana A, Spinelli AE, Canciani B, Brunelli S, Ravazzolo R, Bocciardi R
Disease Models & Mechanisms - vol. 9 685-696 (2016)
Deyon-Jung L, Morice C, Chéry F, Gay J, Langer T, Frantz M, Rozot R, Dalko-Csibe M
Med. Chem. Commun. - vol. 7 506-511 (2016)
Druzhyna N, Szczesny B, Olah G, Módis K, Asimakopoulou A, Pavlidou A, Szoleczky P, Gerö D, Yanagi K, Törö G, López-garcía I, Myrianthopoulos V, Mikros E, Zatarain JR, Chao C, Papapetropoulos A, Hellmich MR, Szabo C
Pharmacological Research - vol. 113 18-37 (2016)
Chypre M, Seaman J, Cordeiro OG, Willen L, Knoop KA, Buchanan A, Sainson RCA, Williams IR, Yagita H, Schneider P, Mueller CG
Immunology Letters - vol. 171 5-14 (2016)
Antibodies play an important role in therapy and investigative biomedical research. The TNF-family member Receptor Activator of NF-??B (RANK) is known for its role in bone homeostasis and is increasingly recognized as a central player in immune regulation and epithelial cell activation. However, the study of RANK biology has been hampered by missing or insufficient […]
Ngo T, Kufareva I, Coleman JLJ, Graham RM, Abagyan R, Smith NJ
British Journal of Pharmacology - vol. 173 2934-2951 (2016)
Seguin A, Monnier VV, Palandri A, Bihel FF, Rera M, Schmitt M, Camadro JM, Tricoire HH, Lesuisse E
Oxidative Medicine and Cellular Longevity - vol. ID 565140 1-11 (2015)
Friedreich’s ataxia (FA) is a rare neurodegenerative disease which is very debilitating for the patients who progressively lose their autonomy. The lack of efficient therapeutic treatment of the disease strongly argues for urgent need to search for new active compounds that may stop the progression of the disease or prevent the appearance of the symptoms […]
Zeniou M, F??ve M, Mameri S, Dong J, Salom?? C, Chen W, El-Habr EA, Bousson F, Sy M, Obszynski J, Boh A, Villa P, Kahn SA, Didier B, Bagnard D, Junier MP, Chneiweiss H, Haiech J, Hibert M, Kilhoffer MC, Heeschen C
PLoS ONE 1-35 (2015)
Cancer stem-like cells reside in hypoxic and slightly acidic tumor niches. Such microenvironments favor more aggressive undifferentiated phenotypes and a slow growing « quiescent state » which preserves them from chemotherapeutic agents that essentially target proliferating cells. Our objective was to identify compounds active on glioblastoma stem-like cells, including under conditions that mimick those found in vivo […]
Yi NY, He Q, Caligan TB, Smith GR, Forsberg LJ, Brenman JE, Sexton JZ
Assay and drug development technologies - vol. 13 558-569 (2015)
Diabetes currently affects 9.3% of the U.S. population totaling $245 billion annually in U.S. direct and indirect healthcare costs. Current therapies for diabetes are limited in their ability to control blood glucose and/or enhance insulin sensitivity. Therefore, innovative and efficacious therapies for diabetes are urgently needed. Herein we describe a fluorescent insulin reporter system (preproinsulin-mCherry, […]
Oprea TI, Sklar LA, Agola JO, Guo Y, Silberberg M, Roxby J, Vestling A, Romero E, Surviladze Z, Murray-Krezan C, Waller A, Ursu O, Hudson LG, Wandinger-Ness A
PLoS ONE - vol. 10 1-32 (2015)
Rho family GTPases (including Rac, Rho and Cdc42) collectively control cell proliferation, adhesion and migration and are of interest as functional therapeutic targets in numerous epithelial cancers. Based on high throughput screening of the Prestwick Chemical Library® and cheminformatics we identified the R-enantiomers of two approved drugs (naproxen and ketorolac) as inhibitors of Rac1 and […]
